![]() ![]() ![]() In postmenopausal women with unknown osteoporosis or osteopenia status, both long-term oral estrogen and estrogen/progestin reduced clinical fractures (high SOE) and hip fractures (moderate SOE). In women with osteopenia or osteoporosis, 6 years of zoledronate reduced incident clinical fractures (HR 0.73 ) (moderate SOE) and clinical vertebral fractures (HR 0.41 ) (moderate SOE). In women with osteoporosis, 4 years of alendronate reduced clinical fractures (hazard ratio 0.64 ) (moderate SOE) and radiographic vertebral fractures (HR 0.50 ) (moderate SOE), while 4 years of raloxifene reduced clinical vertebral fractures (relative risk 0.58 ) (high SOE), but not hip (moderate SOE) or nonvertebral fractures (high SOE). Sixty-one English-language studies were included. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2023
Categories |